1,779 results match your criteria: "Chiba Cancer Center.[Affiliation]"
Expert Opin Pharmacother
January 2025
Department of Neurology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.
Background: Chemotherapy-induced peripheral neuropathy (CIPN) and its associated pain negatively affect patient outcomes and quality of life (QoL). The two-part MiroCIP study included interventional and prospective observational studies. Here, we report the latter, describing CIPN incidence, risk factors, and outcomes.
View Article and Find Full Text PDFActa Paediatr
January 2025
Department of Clinical Epidemiology and Health Economics, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Aim: Some countries are hesitant to implement routine varicella vaccination for children because of concerns over the exogenous boosting hypothesis, which suggests that vaccinating children may increase herpes zoster cases in adults. However, substantial evidence supporting this hypothesis is lacking. This study assessed the association between a child's varicella vaccination status and herpes zoster occurrence in adults in the same household.
View Article and Find Full Text PDFHematol Oncol
January 2025
Department of Hematology, Chiba University Hospital, Chiba, Japan.
POEMS syndrome is a multisystemic disease associated with monoclonal plasma cell disorders. Although the presence of bone lesions is included in the diagnostic criteria, their precise manifestations remain unknown. Here, we retrospectively analyzed the bone lesions in patients with POEMS syndrome and evaluated their clinical features.
View Article and Find Full Text PDFBr J Haematol
January 2025
Department of Nursing, Tohoku Fukushi University, Sendai, Japan.
Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study. This phase II study evaluated the efficacy and safety of zandelisib for relapsed or refractory follicular lymphoma or marginal zone lymphoma. Sixty-one patients received zandelisib orally at 60 mg daily continuously in the first two 28-day cycles, followed by intermittent dosing on Days 1-7 following each cycle until progressive disease or unacceptable toxicity.
View Article and Find Full Text PDFPharmacoepidemiol Drug Saf
January 2025
Department of Clinical Epidemiology & Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Purpose: To assess adverse neurological risks following influenza vaccination in older adults.
Methods: Using a linked database of healthcare administrative claims data and vaccination records from an urban city in Japan (April 1, 2014, to March 31, 2020), we conducted an observational study utilizing a self-controlled case series design. We identified individuals aged ≥ 65 years who experienced adverse neurological outcomes, defined as hospitalizations related to epilepsy, paralysis, facial paralysis, neuralgia, neuritis, optic neuritis, migraine, extrapyramidal disorders, Guillain-Barre syndrome, or narcolepsy.
Jpn J Clin Oncol
January 2025
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Background: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity in chemotherapy contributes to confirm generalizability and reliability of the study itself. However, there have been no studies conducted to assess the heterogeneity among participating centers in randomized phase III trials for biliary tract cancer.
View Article and Find Full Text PDFBackground: In TALAPRO-2, the poly(ADP-ribose) polymerase inhibitor talazoparib plus the androgen receptor-signaling inhibitor enzalutamide improved radiographic progression-free survival (rPFS) versus placebo plus enzalutamide (hazard ratio [HR] = 0.63; 95% CI, 0.51-0.
View Article and Find Full Text PDFRespir Investig
January 2025
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
N Engl J Med
December 2024
From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (K.L.J.); University Hospitals Leuven, Leuven, Belgium (P.N.); Hospital María Curie, Buenos Aires (M.L.C.); Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (S.-B.K.); National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan (E.T.); Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels (P.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (C.S.); Baylor University Medical Center, Texas Oncology, U.S. Oncology, Dallas (J.O.); the Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, Ludwig Maximilians University Munich University Hospital, Munich, Germany (N.H.); the University of North Carolina at Chapel Hill, Chapel Hill (L.A.C.); the University of Milan, Milan (G.C.); the European Institute of Oncology, IRCCS, Milan (G.C.); Hospital Arnau de Vilanova, Valencia, Spain (A.L.-C.); Garvan Institute of Medical Research and University of New South Wales, Sydney (E.L.); Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City (M.L.G.T.); Yonsei University College of Medicine, Seoul, South Korea (J.S.); the Mastology Department, Women's Health Hospital, São Paulo (A.M.); Harbin Medical University Cancer Hospital, Harbin, China (Q.Z.); National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei (C.-S.H.); the Division of Breast Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan (C.-C.H.); Filios Alta Medicina, Monterrey, Mexico (J.L.M.R.); the Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain (M.R.B.); the Department of Breast Surgery, Chiba Cancer Center Hospital, Chiba, Japan (R.N.); Eli Lilly, Indianapolis (K.R.P., C.C.L., E.B., S.C., X.A.W., L.M.S.); and Institut Curie and University of Versailles Saint-Quentin-en-Yvelines-Paris-Saclay University, Paris (F.-C.B.).
Background: Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα ().
Methods: In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, administered alone or with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Patients were assigned in a 1:1:1 ratio to receive imlunestrant, standard endocrine monotherapy, or imlunestrant-abemaciclib.
Int J Clin Oncol
December 2024
Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-City, Chiba, 2608670, Japan.
Background: This study investigated the characteristics of prostate-specific antigen (PSA) dynamics when androgen receptor signaling inhibitor (ARSI), or vintage agent (bicalutamide) was used for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Patients And Methods: A total of 213 mHSPC patients from each of the ARSI and bicalutamide groups treated between 2015 and 2022 were selected from multiple institutions using propensity score-matched analysis to align backgrounds. PSA progression-free survival (PFS) and overall survival (OS) were assessed.
J Gastroenterol
January 2025
Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Background: Lymphovascular invasion (LVI) or pT1b is noncurative after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC), and therefore surgery or chemoradiotherapy (CRT) is recommended. However, there has been debate regarding which treatment has better outcomes and whether individual risks should be considered.
Methods: This was a multicenter, retrospective study conducted at 65 hospitals in Japan.
J Intensive Care
December 2024
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Jpn J Infect Dis
November 2024
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Japan.
In 2021, vaccines against SARS-CoV-2 were developed, and the Omicron variant emerged. This study compared the characteristics, treatments, and mortality of patients with coronavirus disease 2019 (COVID-19) between 2022 and 2020-2021, using administrative claims data linked with vaccine records in a Japanese city. We identified patients underwent COVID-19 antigen or polymerase chain reaction tests and were diagnosed with COVID-19.
View Article and Find Full Text PDFGastric Cancer
January 2025
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Head Neck Pathol
November 2024
Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.
J Atheroscler Thromb
November 2024
Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute.
Aim: We examined the association between dairy intake and all-cause, cancer, and cardiovascular disease mortality in a cohort of the general population followed up for 12 years across Japan.
Methods: We conducted a longitudinal cohort study of 79,715 participants from the Japan Multi-Institutional Collaborative Cohort study (57.2% women, mean age 54.
Cancer Med
November 2024
Department of Urology, Toho University Sakura Medical Center, Sakura, Japan.
Circ Rep
November 2024
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo Tokyo Japan.
Background: Constipation often coexists with heart failure (HF) and can cause increased blood pressure variability, which may increase the risk of repeated HF admissions. However, large-scale contemporary data regarding the prognostic effect of constipation in patients with HF are lacking.
Methods And Results: We retrospectively identified 556,792 patients admitted for HF for the first time and discharged alive in the fiscal years 2016-2021 using the Japanese Diagnosis Procedure Combination database.
BJC Rep
January 2024
Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan.
Background: Nivolumab with modified FOLFIRINOX (mFOLFIRINOX) may have additive antitumour effects while minimising chemotherapy cytotoxicity. We assessed the efficacy and safety of nivolumab+mFOLFIRINOX in metastatic pancreatic cancer.
Methods: Thirty-one treatment-naïve patients aged ≥20 years with metastatic unresectable/recurrent pancreatic cancer (≥1 measurable lesion per Response Evaluation Criteria in Solid Tumours version 1.
BJC Rep
July 2024
Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Background: While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of circulating tumor DNA (ctDNA) as a modality of therapeutic decision-making in advanced GIST.
Methods: We conducted a pooled analysis of SCRUM-Japan studies for advanced GIST patients.
Genes Chromosomes Cancer
November 2024
Division of Surgical Pathology, Chiba Cancer Center, Chiba, Japan.
Angiosarcoma (AS) is a malignant vascular neoplasm comprising neoplastic endothelial cells accounting for 1%-4% of soft tissue sarcomas. While lymphedema-associated and post-irradiation ASs are almost always driven by a high-level amplification of MYC (8q24), sporadic ASs, including those of breast parenchymal origin, typically lack MYC amplification. Here, we report a case of sporadic breast MYC-amplified AS in a 19-year-old female with no history of lymphedema or irradiation, who was referred to our hospital for an enlarging right breast mass.
View Article and Find Full Text PDFCancer Diagn Progn
November 2024
Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Background/aim: Although the impact of body composition on cancer treatment outcomes of patients with cancer has been increasingly reported, it is still unclear whether the radiodensity of subcutaneous adipose tissue (SAT) on computed tomography (CT) images has a prognostic impact on patients with gastric cancer. We measured muscle and SAT profiles on CT and performed an integrated analysis with clinicopathologic factors.
Patients And Methods: We retrospectively analyzed 230 patients with gastric cancer who underwent gastrectomy between June 2016 and December 2020.
Jpn J Clin Oncol
November 2024
Department of Advanced Medical Sciences, Oita University Faculty of Medicine, Oita, Japan.
Adv Pharm Bull
October 2024
Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Sleman, Yogyakarta, Indonesia.
Purpose: The HLF and HuH-6 cell lines represent hepatocellular carcinoma (HCC) with different characteristics in chromosome content that may give different drug responses. Here, PGV-1 was intended to challenge the growth-suppressing effect on HLF and HuH-6 and trace the molecular target mechanism of action compared to sorafenib.
Methods: We applied MTT cytotoxic assay, colony forming assay, flow cytometry analysis, immunofluorescence assay and western blot assay.